In conclusion, our study proved that high expression of ADAM15 correlates with a poor outcome for NSCLC patients, and shed light on the mechanistic interaction between ADAM15 and CD151 in NSCLC carcinogenesis. This evidence concerns the gene ADAM15 and non-small cell lung carcinoma.